<SEC-DOCUMENT>0001628280-23-029166.txt : 20230814
<SEC-HEADER>0001628280-23-029166.hdr.sgml : 20230814
<ACCEPTANCE-DATETIME>20230814061211
ACCESSION NUMBER:		0001628280-23-029166
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230814
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230814
DATE AS OF CHANGE:		20230814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		231166058

	BUSINESS ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393
		BUSINESS PHONE:		8004493353

	MAIL ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rmti-20230814.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:e50a4ac1-ce59-4539-b425-4298bebe9a55,g:c32c9e6e-58b0-479c-90b8-783bbe057a49,d:e92907acacbc4390a18b99c832783ca6--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rmti-20230814</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001041024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rmti-20230814.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie92907acacbc4390a18b99c832783ca6_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 14, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ROCKWELL MEDICAL,&#160;INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-23661</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">38-3317208</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">30142 S. Wixom Road</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Wixom</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Michigan</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">48393</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">248</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">960-9009</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:454.50pt"><tr><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:427.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:454.50pt"><tr><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:427.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:484.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:484.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title&#160;of&#160;Each&#160;Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading&#160;Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name&#160;of&#160;Each&#160;exchange&#160;on&#160;which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">RMTI</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;2.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 14, 2023, Rockwell Medical, Inc. issued a press release and earnings presentation announcing its financial results for the quarter ended June 30, 2023. The press release and earnings presentation are furnished as Exhibit 99.1 to this Current Report on Form 8&#8209;K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 incorporated in this Form 8-K shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Item&#160;9.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Exhibits&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following exhibit is being furnished herewith:</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT&#160;INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991-rmtiq22023earningspr.htm">Press Release, dated August 14, 2023</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROCKWELL MEDICAL,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 14, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Mark Strobeck</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Strobeck</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-rmtiq22023earningspr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7a0c70be848b419c8b037e2201bb96f9_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2.jpg" src="image_2.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:115%">Rockwell Medical Announces Second Quarter 2023 Results </font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;padding-left:13.8pt">Net sales for the six months ended June 30, 2023 was $37.7 million, an 8% increase over $34.8 million for the same period in 2022.</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;padding-left:13.8pt">Gross profit for the six months ended June 30, 2023 was $3.6 million, a 260% increase over $1.0 million for the same period in 2022. Gross margin for the six months ended June 30, 2023 was approximately 10%, a 233% increase over 3% for the same period in 2022.</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;padding-left:13.8pt">Subsequent to the second quarter of 2023, Rockwell Medical acquired a profitable and fully automated hemodialysis concentrates business from Evoqua Water Technologies. The acquisition significantly expands Rockwell Medical's geographic footprint, customer base, and product offerings. At the time of the transaction, Evoqua generated annual revenue of $18 million and $3.3 million in annual EBITDA.  Along with synergies, Rockwell Medical expects this business to deliver 20% to 22% EBITDA margin to the Company.</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;padding-left:13.8pt">With the completion of the Evoqua hemodialysis concentrates business acquisition, Rockwell Medical increased its 2023 net sales guidance from between $78.0 million and $82.0 million to between $82.0 million and $86.0 million&#59; and is increasing 2023 gross profit guidance from between $7.0 million and $9.0 million to between $8.0 million and $10.0 million.</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;padding-left:13.8pt">Rockwell Medical expects to achieve profitability from operations in the fourth quarter of 2023 and going forward.</font></div><div style="margin-top:9pt"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Wixom, Michigan, August 14, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> &#8211; Rockwell Medical, Inc. (the &#34;Company&#34;) (Nasdaq&#58; RMTI), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, today announced financial results and business updates for the three and six months ended June 30, 2023. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#34;In just over a year, we have made great strides in increasing revenue, reducing expenses, and driving the Company towards profitability,&#34; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">said Mark </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Strobeck, Ph.D., Rockwell Medical&#8217;s President and CEO. &#34;By acquiring Evoqua Water Technologies'  profitable, revenue-generating hemodialysis concentrates business, we now expect to be profitable in the fourth quarter of 2023 and going forward. This puts Rockwell Medical in a stronger, more stable financial position to further enhance shareholder value and pursue additional growth opportunities.&#34; </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:115%">FINANCIAL HIGHLIGHTS</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Net sales for the six months ended June 30, 2023 were $37.7 million, which represents an 8% increase over $34.8 million for the same period in 2022. Overall, product revenue for the six months ended June 30, 2023 was $36.1 million compared to product revenue of $33.1 million for the three months ended June 30, 2022, an increase of $3.0 million. Net sales for the three months ended June 30, 2023 were $18.1 million compared to net sales of $19.7 million for the three months ended March 31, 2023 and $18.7 million for the second quarter in 2022. The difference between first quarter 2023 net sales and second quarter 2023 net sales is a result of product revenue recognition timing.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Gross profit for the six months ended June 30, 3023 was $3.6 million, a 278% increase over $1.0 million for the same period in 2022. Gross profit increased by $2.6 million primarily due to restructuring of supply contracts, onboarding of new customers, increased pricing to other </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2.jpg" src="image_2.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">customers, and recognition of the remaining deferred revenue related to the termination of the Baxter distribution agreement. Gross profit for the three months ended June 30, 2023 was $1.0 million compared to gross profit of $2.6 million for the three months ended March 31, 2023 and $1.7 million for the second quarter of 2022. The difference between first quarter 2023 gross profit and second quarter 2023 gross profit is a result of product revenue recognition timing.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">For the six months ended June 30, 2023, Rockwell's net loss was $5.1 million compared to $12.1 million for the same period in 2022. For the three months ended June 30, 2023, Rockwell's net loss was $3.3 million, or $0.18** per share, compared with a net loss of $5.0 million, or $0.43** per share for the same period in 2022. </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Cash and cash equivalents and investments available-for-sale at June 30, 2023 was $14.9 million compared to cash and cash equivalents and investments available-for-sale of $16.8 million at March 31, 2023 and $21.5 million at December 31, 2022. On July 10, 2023, which was after the end of the second quarter of 2023, Rockwell received gross proceeds of approximately $13.8 million from the exercise of warrants, which the Company used to fund the Evoqua hemodialysis concentrates business acquisition. Rockwell acquired from Evoqua substantially all of the assets related to Evoqua's business of manufacturing, marketing, distributing, and selling hemodialysis concentrates products in powder and liquid form for $11.0 million up front in cash plus approximately $1.2 million for the estimated inventory amount. Following the close of the Evoqua transaction and taking into account the exercised warrants, Rockwell had approximately $16.2 million in cash and cash equivalents and investments available-for-sale on a pro forma basis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Highlights</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.821%"><tr><td style="width:1.0%"></td><td style="width:37.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Three Months Ended<br>June 30</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Six Months Ended<br>June 30</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:125%">(In Thousands, Except Per Share Amounts)</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net Sales</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,080&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,682&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">37,748&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">34,806&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Gross Profit</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,033&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,745&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,632&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">960&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net Loss</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,305)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4,967)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(5,055)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(12,128)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Adjusted EBITDA*</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,257)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,363)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,234)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(10,028)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Basic and Diluted Net Loss per Share **</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.18)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.43)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.27)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1.20)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">* &#160;&#160;&#160;&#160;See reconciliation to GAAP financial measures in the tables below.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">** </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Please see the &#34;Loss Per Share&#34; section in Note 3 on Form 10-Q filed August 14, 2023 for more details on what is included in the basic and diluted net loss per share calculation.</font></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:115%">BUSINESS HIGHLIGHTS</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Rockwell Medical entered into three-year co-promotion services agreement with B. Braun Medical Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">As part of the agreement, Rockwell Medical designated B. Braun as an independent, non-exclusive representative to promote the Company's hemodialysis concentrates products to dialysis providers in the United States, with a focus on the west coast. All terms of the sale of any Rockwell Medical product, including price, delivery schedule, and terms and </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2.jpg" src="image_2.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">conditions, are set by Rockwell Medical, in the Company's sole discretion. All orders will be directed to, and processed by, Rockwell Medical. B. Braun will receive a fee for any sales generated by its promotional efforts. </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Rockwell Medical was added to the Russell Microcap Index.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Rockwell Medical expanded its international footprint for its hemodialysis concentrates products through several multi-year distribution and user agreements. New geographies include the </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">United Arab Emirates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Chile, St. Lucia, Costa Rica, and Grenada. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rockwell has a large and growing international business and currently sells its hemodialysis concentrates products in 29 countries throughout </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">North America, South America, Asia and Africa.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Rockwell Medical&#8217;s subsidiary, Rockwell Transportation (DOT #685854) received the highest safety rating by the Federal Motor Carrier Safety Administration (&#34;FMCSA&#34;), an Operating Administration within the U.S. Department of Transportation. Safety ratings are based on an evaluation of a motor carrier's compliance with the safety fitness standard as described in </font><font style="background-color:#ffffff;color:#0432ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">49 CFR 385, Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">During and subsequent to the second quarter of 2023, Rockwell undertook workforce and cost reductions as part of its continued business restructuring.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">On July 10, 2023, Rockwell Medical acquired the hemodialysis concentrates business from Evoqua. Under the terms of the agreement, Rockwell Medical acquired Evoqua's concentrates business which includes all contracts, all intellectual property, all U.S. Food and Drug Administration 510(k) clearances, and all assets primarily associated with, and related to, Evoqua's concentrates business nationwide, including liquid and powder bicarbonate and liquid acid. Evoqua's operations are fully automated and afford Rockwell the potential to manufacture its hemodialysis concentrates products at a lower cost and add significant capacity to the Company's production line. By assuming responsibility for Evoqua&#8217;s concentrates customer contracts, Rockwell has further expanded its footprint in the United States and assumed a larger market share of the already growing hemodialysis concentrates market. Additionally, the Company is now the leading supplier of liquid bicarbonate products to dialysis centers in the United States.  </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:115%">2023 GUIDANCE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">With the addition of Evoqua's hemodialysis concentrates business, which closed on July 10, 2023, and after evaluating the expected synergies between Rockwell Medical's and Evoqua's hemodialysis concentrates businesses and product lines, the Company updates its 2023 guidance as follows&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:13.8pt">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> &#8212; The Company increased its 2023 net sales guidance from between $78.0 million and $82.0 million to between $82.0 million and $86.0 million. Rockwell Medical anticipates that third quarter 2023 net sales will be between $21.0 million and $23.0 million.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:13.8pt">Gross Profit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8212; The Company is increasing its 2023 gross profit guidance from between $7.0 million and $9.0 million to between $8.0 million and $10.0 million. </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:13.8pt">Profitability </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8212; Since Rockwell Medical announced its </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">updated business strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> in November 2022, the Company provided guidance that it expected to achieve profitability in 2024. Rockwell Medical is updating its guidance on profitability and now expects the Company to be profitable </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2.jpg" src="image_2.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">in the fourth quarter 2023 and going forward. <br></font></div><div style="margin-top:9pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.410%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Initial 2023 Guidance</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Updated 2023 Guidance</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Net Sales</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">$78.0 Million to $82.0 Million</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">$82.0 Million to $86.0 Million</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Gross Profit</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">$7.0 Million to $9.0 Million</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">$8.0 Million to $10.0 Million</font></div></td></tr></table></div><div style="margin-top:9pt;padding-left:36pt"><font><br></font></div><div style="margin-top:9pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:115%">CONFERENCE CALL AND WEBCAST DETAILS</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Date&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Monday, August 14, 2023</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Time&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 8&#58;00am ET</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Live Number&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (888) 660-6347 &#47;&#47; (International) 1 (929) 201-6594</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Conference Call ID&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> 4944610</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Webcast and Replay&#58; </font><font style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">www.RockwellMed.com&#47;Results</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Speakers&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Mark Strobeck, Ph.D. &#8212; President and Chief Executive Officer&#59; and </font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Paul McGarry, CPA &#8212; SVP, Finance and Chief Accounting Officer.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Format&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Discussion of second quarter 2023 operational and financial results followed by Q&#38;A.</font></div><div style="margin-top:9pt"><font><br></font></div><div style="margin-top:9pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">About Rockwell Medical<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rockwell Medical, Inc. (Nasdaq&#58; RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient&#8217;s home. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Rockwell Medical is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States and intends to become the leading global supplier of hemodialysis concentrates. Certified as a Great Place to Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> in 2023, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Rockwell Medical is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Driven to Deliver Life-Sustaining Dialysis Solutions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For more information, visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">www.RockwellMed.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Forward-Looking Statements<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Certain statements in this press release may constitute &#34;forward-looking statements&#34; within the meaning of the federal securities laws. Words such as, &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;should,&#34; &#34;believe,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;estimate,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;can,&#34; &#34;would,&#34; &#34;develop,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2.jpg" src="image_2.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#34;forecast,&#34; &#34;project,&#34; &#34;intend,&#34; &#34;look forward to,&#34; &#34;remain confident,&#34; &#8220;guidance,&#8221; or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">There can be no assurance that&#58; Rockwell Medical will grow its hemodialysis concentrates business and further improve its performance&#59; Rockwell Medical will be able to enhance the economics in its current customer agreements&#59; Rockwell Medical will add new long-term supply agreements with new customers and will transition Baxter customers&#59; Rockwell Medical will achieve its projected total net sales and gross profit for 2023&#59; Rockwell Medical will be able to achieve planned cost savings to operate its concentrates business profitability or achieve the other components of its strategy&#59; Rockwell Medical will achieve profitability in the fourth quarter of 2023&#59; Rockwell Medical will expand into new product categories and markets&#59; Rockwell Medical will be successful in evaluating potential business development opportunities&#59; that Rockwell Medical will realize benefits from the Baxter transition&#59; Rockwell Medical will successfully integrate the Evoqua hemodialysis concentrates business and realize synergies and cost savings from that acquisition&#59; or Rockwell Medical&#8217;s future cash balance will be sufficient to fund operations going forward. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include but are not limited to those risks more fully discussed in the &#34;Risk Factors&#34; section of our Annual Report on Form 10-K for the year ended December 31, 2022, as such description may be amended or updated in any subsequent reports filed with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">To supplement the Company&#8217;s financial results presented on a U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA as useful operating metrics. The Company believes that the presentation of these non-GAAP financial measures, when viewed with results under GAAP and the accompanying reconciliation, provides supplementary information to analysts, investors, lenders, and the Company&#8217;s management in assessing the Company&#8217;s performance and results from period to period. The Company uses these non-GAAP measures internally to understand, manage and evaluate the Company&#8217;s performance. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.<br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"># # #</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CONTACT&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Heather R. Hunter </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SVP, Chief Corporate Affairs Officer</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(248) 432-1362</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">IR&#64;RockwellMed.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2.jpg" src="image_2.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Financial Tables Follow</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"># # #</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2.jpg" src="image_2.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.702%"><tr><td style="width:1.0%"></td><td style="width:60.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.233%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</font></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(Dollars In Thousands)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">June 30,</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, </font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(Unaudited)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash and Cash Equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">14,865&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">21,492&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total Assets</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">38,037&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">46,635&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total Liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">28,509&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32,529&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total Stockholders&#8217; Equity </font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,528&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">14,106&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common Stock Outstanding</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">16,795,673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12,163,673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock and common stock equivalents*</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32,033,132&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31,356,373&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">*Common stock and common stock equivalents&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">16,795,673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12,163,673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock warrants (pre-funded)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,793,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,300,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock and pre-funded stock warrants</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,588,673&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,463,673&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Preferred stock converted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,363,636&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,363,636&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Options to purchase common stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,570,599&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,206,905&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Restricted stock awards</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">891&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">891&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Restricted stock units</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">313,065&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">125,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock warrants</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,196,268&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,196,268&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total common stock and common stock equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32,033,132&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31,356,373&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Our capital structure as of August 14, 2023, which includes the Warrant Exercise and Reload Warrant transaction executed on July 10, 2023 is as follows&#58;</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"></td><td style="width:83.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">Common Stock Outstanding&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total Outstanding Common Stock</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">28,489,663</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">Common Stock Equivalents Outstanding&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Options and unvested RSU's</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,884,555</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Preferred Stock - convertible to common at $11 per share</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,363,636</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warrants</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">- Armistice Warrant Reload - strike $5.13 per share - exp. Dec 2027</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,750,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">- All other warrants</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">295,278</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total Common Stock equivalents</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,293,469</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total - Fully Diluted Shares</font></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">35,783,132</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2.jpg" src="image_2.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:35.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</font></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS</font></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(In Thousands, Except Shares and Per Share Amounts)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Three Months Ended June 30,&#160;2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Three Months Ended June 30,&#160;2022</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Six Months Ended June 30,&#160;2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Six Months Ended June 30,&#160;2022</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net Sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,080&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,682&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">37,748&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">34,806&#160;</font></td><td style="border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cost of Sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">17,047&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">16,937&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">34,116&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">33,846&#160;</font></td><td style="border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gross Profit (Loss)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,033&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,745&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,632&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">960&#160;</font></td><td style="border-right:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and Product Development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">167&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">926&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">445&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,494&#160;</font></td><td style="border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Selling and Marketing</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">530&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">526&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,028&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">981&#160;</font></td><td style="border-right:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and Administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,295&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,775&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,545&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,592&#160;</font></td><td style="border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Operating Loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,959)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4,482)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4,386)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(11,107)</font></td><td style="border-right:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #d9d9d9;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Other (Expense) Income </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Realized Gain on Investments</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4&#160;</font></td><td style="border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest Expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(395)</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(485)</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(782)</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,025)</font></td><td style="border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest Income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">113&#160;</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total Other Expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(346)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(485)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(669)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,021)</font></td><td style="border-right:1pt solid #d9d9d9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net Loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,305)</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4,967)</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(5,055)</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #d9d9d9;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(12,128)</font></td><td style="border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Basic and Diluted Net Loss per Share</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.18)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.43)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.27)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1.20)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Basic and Diluted Weighted Average Shares Outstanding</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,496,640&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,591,768&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,480,248&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #d9d9d9;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #d9d9d9;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,076,415&#160;</font></td><td style="border-right:1pt solid #d9d9d9;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:5pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:5pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:5pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:5pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.452%"><tr><td style="width:1.0%"></td><td style="width:37.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Reconciliation to GAAP Financial Measures</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Adjusted EBITDA</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three Months Ended<br>June 30</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Six Months Ended<br>June 30</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(in thousands)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net Loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(3,305)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(4,967)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(5,055)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(12,128)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">303&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">393&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">603&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">837&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Depreciation and amortization</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">232&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">512&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">462&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">EBITDA</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,740)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4,342)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,940)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(10,829)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">One time severance costs</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">171&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">884&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">201&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">884&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stock-based compensation</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">312&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">95&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">505&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(83)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Adjusted EBITDA</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,257)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,363)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,234)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(10,028)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rmti-20230814.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e50a4ac1-ce59-4539-b425-4298bebe9a55,g:c32c9e6e-58b0-479c-90b8-783bbe057a49-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rmti="http://rockwellmed.com/20230814" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://rockwellmed.com/20230814">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20230814_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20230814_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://rockwellmed.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rmti-20230814_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e50a4ac1-ce59-4539-b425-4298bebe9a55,g:c32c9e6e-58b0-479c-90b8-783bbe057a49-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_1b6aa28f-bd7f-4500-af3d-4592a3aea4ae_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_acf98f23-9cf2-4fce-88e2-1bdbe178e971_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_489157fc-827f-403b-a2b6-09201cc123a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8148de44-4106-4097-ae69-50e2a93ea6ca_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f68a6eea-1a94-4db8-bb09-ac76fc3855b8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d8ca55b5-0249-4557-9b86-6f2745c74aff_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_66407bc8-d41d-4103-9490-adcfc1736f1e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_77336428-143e-4adf-8385-06edb2215cad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c422ee83-5804-491e-9b36-d24e1ef7a5f9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d28231f8-b0ea-4d6b-9ff4-ca30ce303b6c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7190d463-1850-45e8-a3be-3b083e9d682e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c5c52f87-bf68-4bae-91fb-b3de1c62590f_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_dc4a7a0b-d1eb-4bea-8358-85d7dacf984b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fc4a00a8-7338-42f2-95f4-2339fedcffaa_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c021573f-1a29-44a2-9560-5a115c87a588_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f635e4ad-7da7-472e-bb8f-4809a9a454f5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a7ac4718-a301-4b94-93b0-2eed6c7cc8e8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1cbeca07-83a8-4f02-b947-dea00ff004c8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6cc700e1-4ad0-471b-8257-feff1d4f1cc3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2b2ab7a9-59c2-4885-93f1-29543389fa9c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8cb79731-0d33-485c-a772-88a7c44c7902_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7b763150-c0dd-4707-9b27-de99647b662c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ef3b6559-45aa-49e5-a5bb-d4e5bb40f5f2_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rmti-20230814_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e50a4ac1-ce59-4539-b425-4298bebe9a55,g:c32c9e6e-58b0-479c-90b8-783bbe057a49-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://rockwellmed.com/role/Cover" xlink:type="simple" xlink:href="rmti-20230814.xsd#Cover"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1607cc59-5aec-41a6-baf6-aace78d2b9dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_DocumentType_1607cc59-5aec-41a6-baf6-aace78d2b9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_105653d6-972a-4cb1-87c1-5a0cf872d631" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_DocumentPeriodEndDate_105653d6-972a-4cb1-87c1-5a0cf872d631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_62fe2183-7543-4051-9e26-5ea2a036ed47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_EntityRegistrantName_62fe2183-7543-4051-9e26-5ea2a036ed47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b9d68198-c6c3-410e-8e10-4ad0f62c03ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b9d68198-c6c3-410e-8e10-4ad0f62c03ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_bf64f9ab-dae9-486c-a4e8-c1027461ff3d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_EntityFileNumber_bf64f9ab-dae9-486c-a4e8-c1027461ff3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_df28871b-d37f-44af-9074-677137b55504" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_EntityTaxIdentificationNumber_df28871b-d37f-44af-9074-677137b55504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7ab27022-75f3-4da3-8fa8-a9e9389b287f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_EntityAddressAddressLine1_7ab27022-75f3-4da3-8fa8-a9e9389b287f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ccbabe4a-ca10-4435-b028-7a5cb6fa80e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_EntityAddressCityOrTown_ccbabe4a-ca10-4435-b028-7a5cb6fa80e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9c468d8c-9f82-423e-90b3-2e0ee4183001" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_EntityAddressStateOrProvince_9c468d8c-9f82-423e-90b3-2e0ee4183001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_af313e19-088a-40f1-8edc-d8d2c10408b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_EntityAddressPostalZipCode_af313e19-088a-40f1-8edc-d8d2c10408b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3859f279-2889-4bd1-987c-97ca0d2ee9c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_CityAreaCode_3859f279-2889-4bd1-987c-97ca0d2ee9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_787a5518-bba9-48bf-a826-5128f474cb69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_LocalPhoneNumber_787a5518-bba9-48bf-a826-5128f474cb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_853dab85-0165-49f3-9341-1d9dab03975f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_WrittenCommunications_853dab85-0165-49f3-9341-1d9dab03975f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_92b9367b-8b27-4972-8466-572ec08c15b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_SolicitingMaterial_92b9367b-8b27-4972-8466-572ec08c15b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_9e71eeed-a14a-4ed8-9310-c4100c803039" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_PreCommencementTenderOffer_9e71eeed-a14a-4ed8-9310-c4100c803039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f9901622-3038-48f7-8a06-e0ebd8266604" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f9901622-3038-48f7-8a06-e0ebd8266604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2444a4e7-51d6-47bf-b811-297f428fa126" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_Security12bTitle_2444a4e7-51d6-47bf-b811-297f428fa126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_be3ff939-4ce8-4fc0-9fe3-2c4dfe668bce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_TradingSymbol_be3ff939-4ce8-4fc0-9fe3-2c4dfe668bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4f79c666-f88d-4fc7-8360-1152736d6692" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_SecurityExchangeName_4f79c666-f88d-4fc7-8360-1152736d6692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b80d5b60-9c66-4409-b22c-68b972f43b76" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_EntityEmergingGrowthCompany_b80d5b60-9c66-4409-b22c-68b972f43b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9bedd516-0c4b-48de-aedd-bc461e81175b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_EntityCentralIndexKey_9bedd516-0c4b-48de-aedd-bc461e81175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ecd85ead-a80e-4eef-9729-d52ff5890572" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a55f5227-ce99-4183-af21-4bf1aa1437de" xlink:to="loc_dei_AmendmentFlag_ecd85ead-a80e-4eef-9729-d52ff5890572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_2.jpg
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MP6BCY#]*B:(C,6YDZQ&.WUF6O!G!.P\X03E!A!5LA-2Q6^F\#%;N'QU*]+J
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M:/CB\,N3E+@@&2*LWQCAW'1YV3Q(=6F9V>DM.ZI>?V7/COH*C=KQ6R E!9D
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M,=4]@B=FM::8(#HQ^$5B?:+($;[?$&7ZE>MT]H[@'5E<7%H'0Z=_1'F [N2
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M3QQNL4*B)J'R1VN1C6&(^S_^[!/B"&:F*4*ZK%7(5$>4EZF!1A+7<O.R*(A
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M[\<-6UM9*JJMSLYY <.)1I\F[UTT0?<0,I-&3L>XH45.$Z\?C9S>4$M+N&^
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M>&CX>A8"I$L4%P*><U(;7N[P,!I-\'D\YOGON66ND\@%G,P;R %8W:F9.TO
MR^HJ,6O%V6D4(X"LD^/@S.>$Y<"9YC#!+8XM+H_B!)I8'*$#_;)$(AG+<0^Q
M?U3>#/3<<.5CANVM0B JICLZO;9*[35J@U;FDP.>AOI"71Q*94.^O-U99 :,
M3!3U*2+Y7WRD%+%>GI8.;X[D^QVR[7T2TQK\7I1YN]@B#XJ0WKG-;Q-Q@3UF
MBPOU +>EU7M<1$[[MW_A).7("%/6S6[>H]2,]/3<O$QBQM6KS _F8W!N%>-
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MHC5LI'>GV? %4-F9$$TJC+&E:?=I!#R0?U0L,30)%S6Z)X$WS !AG-_I1T
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M*4EJ/2^/UB:?M $$! &):4+,QYF!;X9$4<@FEC127J[?Z80VH>Y,3,]V]8W
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A\DE)""0AD(1 $@+_?V=^N>D[9%*(     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139914505798416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 14,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ROCKWELL MEDICAL,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3317208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30142 S. Wixom Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wixom<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">960-9009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMTI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001041024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>rmti-20230814_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rmti-20230814.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001041024</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-08-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ROCKWELL MEDICAL,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-23661</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">38-3317208</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">30142 S. Wixom Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Wixom</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">48393</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">960-9009</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">RMTI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ A3$.5Y>*NQS     $P(
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M_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ A3$.5R0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( (4Q#E=ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " "%,0Y7BF'N_^T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "%,0Y7
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( (4Q#E>>E;5V000  '<0   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "%,0Y7
MGZ ;\+$"  #B#   #0              @ &##   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( (4Q#E>7BKL<P    !,"   +              "  5\/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( (4Q#E>JQ"(6,P$  "("   /
M      "  4@0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "%,0Y7)!Z;
MHJT   #X 0  &@              @ &H$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " "%,0Y799!YDAD!  #/ P  $P
M    @ &-$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #7
%$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rmti-20230814.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="rmti-20230814.htm">rmti-20230814.htm</File>
    <File>ex991-rmtiq22023earningspr.htm</File>
    <File>rmti-20230814.xsd</File>
    <File>rmti-20230814_lab.xml</File>
    <File>rmti-20230814_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rmti-20230814.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "rmti-20230814.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rmti-20230814_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rmti-20230814_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rmti-20230814.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rmti",
   "nsuri": "http://rockwellmed.com/20230814",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20230814.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://rockwellmed.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20230814.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-029166-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-029166-xbrl.zip
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M9H-VCGMN#HB 08=Y[@/7X;_@1]/\18Z=<K7$\DG0!Y -%<N]/<O]1.0B#FS
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M#OT'!$,3WKV\O?BDD5G[Z%#['@1$XCN'<DM=_I_CM]H@BE[JQ3V;AD(\PQZ
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M@V)HP+)R#X_KR[GSF#RT.]HD#I/S><@T:)<,F +7:,Y9^<AQY.&,U@@'BZ8
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MIC7TUE!.?GD]A]F%HWZ;6YGUAHG:EK[M>BY-"_#_T6[_R-7F[S,:8>N1M"L
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M<*C'.YIMO<><![G#DP[ =P+KC\&='8R(S;Q@B(*/A:@>"4D5Y1/I< ^ADH>
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MZF'B8H [6FA(7-:!(>09PIG7P%HIV^VR\ XX.==>)"=8L7PF7P5GE;D\@CC
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M4=I6Z&NWW:WH<+DVWWL+Z 2;K9Z.?@%02P,$%     @ A3$.5[[[=*!S"@
M2UX  !4   !R;71I+3(P,C,P.#$T7VQA8BYX;6S57%%OVS@2?N^OT/E>[H"R
MIBA*(HLVBUZV/127;8,FQ2[N<#!(BDR$M:5 5IKDWQ\EVXD54[9(Q:KN)5;L
MT?";S_J&HR&M=[_<+^;>#UDLTSQ[/_'?P(DG,Y$G:7;U?O+]\A,@DU].7KUZ
M]Q< _OC'MS/OUUS<+F16>J>%9*5,O+NTO/;*:^G]GA=_IC^8=SYGI<J+!0 G
M]6FG^<U#D5Y=EQZ"*-B8;3XMWLH0,LR$#X0,*<!A0 ''* 084<(EEY2%X>NK
MMR) @LI(@I!P"'!,!:"0$Q"3@',)PYAA6CN=I]F?;ZL_G"VEI\/+EO6_[R?7
M97GS=CJ]N[M[<\^+^9N\N)HB"(/IQGJR-K_?L;\+:FN?4CJM/WTT7:8F0^W6
MG_[QV]F%N)8+!M)L6;),5 ,LT[?+^LVS7+"R9OT@+J_5HOH/;,Q ]1;P$0C\
M-_?+9'+RRO-6=!3Y7'Z3RJM>OW_[W#HDG586TTQ>5=_MN2S2/+DH65&>,2[G
M&GWMK7RXD>\GRW1Q,Y>;]ZX+J<QNYT71\%JAI!5*/ZI0_K5ML&D/^"^$M]S%
M^@+@ZG"_O!3&?9Q^>3&XESI#R.,#WAJF-^35!?4Q2X:Z=A^'Z@W]^(A?ZK+(
M2S8?X+)X&F8+\KQZXTP?K8>I'.U)IO4XZ]2]!57>ES)+Y"I;-EQ[:?)^HH]F
MB4QG'[,R+1].]<Q7L/EG?<+]O^3#S.<18X@HP)-8Z;D+0L!4D.@CBEC I)[8
MY*Q\O*AG,@/?+S;CUX,<&&%B$5O9HM%"+O/;0CS-;HNY:<K2LU4UOY%IQA9R
M></6)VB852FP0GZR NFM47HU3$_C?#=]"LF%R/GQZ9F/C)E<-+#,JW(@+YY'
MGXO#T3_I:ZF!UZ$OI7ASE?^8ZG,U!0A5!Z ZJ&75[G&Z\^5]*#8X62$.\+RV
MF(I<USHW)6A0KHI\T3&@,N_XO:^HT\-.O+Q(9*$K6$,(ANOODMU_3K3/5*6K
M*NS+[8++8L:$HD2A %"A$,!*2$"(U/F()USZ,9$T]NT$W3+22(6MT7I-N-X*
MKZW VPCN*O07H&T8P=LSYB#\ VST2 !MG@=.! <"W$T(ATYP30P?DD1?),OU
MBZXNI#_#A/IAK 0@J)KE8< !0SP"D"+H"^&C@$5V2<$PRD@3PAKBZ\V!5X'U
MOF;2-B&8B.V:#'K2-4PBL&?*(1'L8:)'$C!Y'3@![ EL5_S[C.V%?UFPJMUU
M\;#@^7Q&?$P2B3' /HRTV&D,F(PH"*%$C :218)U%7O#\]@$O@;GK=!UEW.3
MKL,2=B;AR++M&+^52(VQ.@FSZ6DP,1H#V!:@V<!UMOV4SN6Z,%0189&4#/B,
M:O$EG #.(05,Q)$2 0E#3NPFV2?G8Y/>>L:H #J6UUO$=9U$W>@89N[LPH3#
M;+D;<H])<LO9P'/C;AB[4Z+!QEZ4YX4\S1<+J7%5:SR?E\M;65Q6[;'BJU+Z
M6DN(8%J((8 (5VLU80PH)Q&(%(IQ*&+,E.HJTD.#C4VT&B\06X"]%6)O!=FK
M,7>7\4&J#\OZ)0D\LLQ[<6<E_*ZD."6"@\X'2PQ=P]Q.%)W/L4\<%_D\%6FI
M"X/?F-9BRN:S*,(PYH* !/M)54P'@&(* 4N$$GX<1,KOW!K?=3^VY/"$T-M
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M)WB\7M8WAJ.;] X3V-YOH3,3N3($,R64P@7<?&N%C"MO:>  QF>C<+AO;1@
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MN3W0?70OPQ_L_!=02P$"% ,4    " "%,0Y7.3Z"N@PL   N7 ( '@
M        @ $     97@Y.3$M<FUT:7$R,C R,V5A<FYI;F=S<'(N:'1M4$L!
M A0#%     @ A3$.5UB3Z5IK#P  R8(  !$              ( !2"P  ')M
M=&DM,C R,S X,30N:'1M4$L! A0#%     @ A3$.5U),(1QM @  ;0<  !$
M             ( !XCL  ')M=&DM,C R,S X,30N>'-D4$L! A0#%     @
MA3$.5[[[=*!S"@  2UX  !4              ( !?CX  ')M=&DM,C R,S X
M,31?;&%B+GAM;%!+ 0(4 Q0    ( (4Q#E=B#= 1KP8  -PP   5
M      "  21)  !R;71I+3(P,C,P.#$T7W!R92YX;6Q02P4&      4 !0!0
) 0  !E

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
